<SEC-DOCUMENT>0002100119-26-001406.txt : 20260731
<SEC-HEADER>0002100119-26-001406.hdr.sgml : 20260731
<ACCEPTANCE-DATETIME>20260731102021
ACCESSION NUMBER:		0002100119-26-001406
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260731
DATE AS OF CHANGE:		20260731

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-60487
		FILM NUMBER:		261226034

	BUSINESS ADDRESS:	
		STREET 1:		660 W. GERMANTOWN PIKE
		STREET 2:		SUITE 110
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		660 W. GERMANTOWN PIKE
		STREET 2:		SUITE 110
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VANGUARD CAPITAL MANAGEMENT LLC
		CENTRAL INDEX KEY:			0002100119
		ORGANIZATION NAME:           	
		EIN:				392877419
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			1231
		LEGAL ENTITY IDENTIFIER:    	529900ZEWTRLEJ6XE960

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		100 VANGUARD BLVD
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		610-669-6148

	MAIL ADDRESS:	
		STREET 1:		100 VANGUARD BLVD
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<schemaVersion>X0202</schemaVersion>
<headerData>
<submissionType>SCHEDULE 13G</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0002100119</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<securitiesClassTitle>Common Stock</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>06/30/2026</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001055726</issuerCik>
<issuerName>Inovio Pharmaceuticals Inc</issuerName>
<issuerCusips>
<issuerCusipNumber>45773H409</issuerCusipNumber>
</issuerCusips>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>660 West Germantown Pike</com:street1>
<com:street2>Suite 110</com:street2>
<com:city>Plymouth Meeting</com:city>
<com:stateOrCountry>PA</com:stateOrCountry>
<com:zipCode>19462</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>
<reportingPersonName>Vanguard Capital Management</reportingPersonName>
<citizenshipOrOrganization>PA</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>511004</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>4161566</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>4161566</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<classPercent>5.05</classPercent>
<typeOfReportingPerson>IA</typeOfReportingPerson>
<comments>
In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.

</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Inovio Pharmaceuticals Inc</issuerName>
<issuerPrincipalExecutiveOfficeAddress>660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, 19462</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>Vanguard Capital Management</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>100 Vanguard Blvd,, Malvern, PA, 19355</principalBusinessOfficeOrResidenceAddress>
<citizenship>PA</citizenship>
</item2>
<item3>
<notApplicableFlag>N</notApplicableFlag>
<typeOfPersonFiling>IA</typeOfPersonFiling>
</item3>
<item4>
<amountBeneficiallyOwned>4161566</amountBeneficiallyOwned>
<classPercent>5.05</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>511004</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>4161566</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>Y</notApplicableFlag>
</item5>
<item6>
<notApplicableFlag>N</notApplicableFlag>
<ownershipMoreThan5PercentOnBehalfOfAnotherPerson>Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11.</certifications>
</item10>
</items>
<signatureInformation>
<reportingPersonName>Vanguard Capital Management</reportingPersonName>
<signatureDetails>
<signature>My Trieu-Gatt</signature>
<title>Authorized Signatory, Head of Global Fund Administration</title>
<date>07/31/2026</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
